[HTML][HTML] 抗CD19 CAR-T 细胞序贯异基因造血干细胞移植术治疗难治B 淋巴细胞白血病疗效及安全性观察
艾昊， 尹青松， 王倩， 符粤文， 魏旭东… - Chinese Journal of …, 2020 - ncbi.nlm.nih.gov
抗CD19 CAR-T细胞序贯异基因造血干细胞移植术治疗难治B淋巴细胞白血病疗效及安全性观察-
PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …
PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …
[HTML][HTML] 伊布替尼联合CAR-T 治疗BCL-2 抑制剂耐药伴del (17p) 慢性淋巴细胞白血病一例报告并文献复习
巩娇娇， 尹青松， 李梦娟， 艾昊， 王倩… - Chinese Journal of …, 2019 - ncbi.nlm.nih.gov
伊布替尼联合CAR-T治疗BCL-2抑制剂耐药伴del(17p)慢性淋巴细胞白血病一例报告并文献复习-
PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …
PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …
Safety and efficacy of patients with refractory B-lymphoblastic leukemia treated with anti-CD19 CAR-T cell bridging to allogeneic hematopoietic stem cell …
H Ai, QS Yin, Q Wang, YW Fu, XD Wei… - Zhonghua xue ye xue za …, 2020 - europepmc.org
Objective: To investigate the efficacy and side effects of anti-CD19 CAR-T cell bridging to
allogeneic hematopoietic stem cell transplantation (allo-HSCT) regimen for refractory B …
allogeneic hematopoietic stem cell transplantation (allo-HSCT) regimen for refractory B …
造血干细胞移植治疗淋巴瘤中国专家共识(2018 版).
邱录贵， 李建勇， 石远凯 - Chinese Journal of Oncology …, 2018 - search.ebscohost.com
虽然近年来单克隆抗体, 小分子靶向药物和免疫治疗等新药的应用明显提高了恶性淋巴瘤患者的
近期疗效和长期生存, 但造血干细胞移植在恶性淋巴瘤的整体治疗中仍然具有重要的地位 …
近期疗效和长期生存, 但造血干细胞移植在恶性淋巴瘤的整体治疗中仍然具有重要的地位 …
Ibrutinib combined with CAR-T cells in the treatment of del (17p) chronic lymphocytic leukemia with BCL-2 inhibitor resistance: A case report and literature review
JJ Gong, QS Yin, MJ Li, H Ai, Q Wang… - Zhonghua xue ye xue …, 2019 - europepmc.org
Objective: To improve the knowledge and experience of ibrutinib combined with CAR-T cells
in the treatment of high-risk chronic lymphoblastic leukemia (CLL) patients or small …
in the treatment of high-risk chronic lymphoblastic leukemia (CLL) patients or small …